within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF03_Durvalumab;

model Durvalumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 6.027777777777778e-08,
    adminDuration = 600,
    adminMass = 1500 / 1000000,
    adminCount = 1,
    Vd = 0.0056,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0033,
    k12 = 3.361111111111111e-08,
    k21 = 3.361111111111111e-08);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Durvalumab</td></tr><tr><td>ATC code:</td><td>L01FF03</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>5.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.217</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Durvalumab is a human monoclonal antibody that blocks programmed death-ligand 1 (PD-L1), thereby enhancing T-cell-mediated immune response against tumor cells. It is primarily used for the treatment of locally advanced or metastatic urothelial carcinoma and non-small cell lung cancer, and is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients (including non-small cell lung cancer, urothelial carcinoma). Parameters reported for intravenous administration in adults.</p><h4>References</h4><ol><li><p>Siu, L, et al., &amp; Hong, DS (2020). Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. <i>Journal for immunotherapy of cancer</i> 8(2) –. DOI:<a href=\"https://doi.org/10.1136/jitc-2020-001095\">10.1136/jitc-2020-001095</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33037117/\">https://pubmed.ncbi.nlm.nih.gov/33037117</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01FF03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Durvalumab;
